|
1
|
McGuire V, Jesser CA and Whittemore AS:
Survival among U.S. women with invasive epithelial ovarian cancer.
Gynecol Oncol. 84:399–403. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li H, Zhang H, Zhao S, Shi Y, Yao J, Zhang
Y, Guo H and Liu X: Overexpression of MACC1 and the association
with hepatocyte growth factor/c-Met in epithelial ovarian cancer.
Oncol Lett. 9:1989–1996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gislefoss RE, Langseth H, Bolstad N,
Nustad K and Morkrid L: HE4 as an early detection biomarker of
epithelial ovarian cancer: Investigations in prediagnostic
specimens from the janus serumbank. Int J Gynecol Cancer.
25:1608–1615. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lawrenson K, Grun B, Lee N,
Mhawech-Fauceglia P, Kan J, Swenson S, Lin YG, Pejovic T, Millstein
J and Gayther SA: NPPB is a novel candidate biomarker expressed by
cancer-associated fibroblasts in epithelial ovarian cancer. Int J
Cancer. 136:1390–1401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Masoumi-Moghaddam S, Amini A, Wei AQ,
Robertson G and Morris DL: Sprouty 2 protein, but not Sprouty 4, is
an independent prognostic biomarker for human epithelial ovarian
cancer. Int J Cancer. 137:560–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stiekema A, Boldingh QJ, Korse CM, van der
Noort V, Boot H, van Driel WJ, Kenter GG and Lok CA: Serum human
epididymal protein 4 (HE4) as biomarker for the differentiation
between epithelial ovarian cancer and ovarian metastases of
gastrointestinal origin. Gynecol Oncol. 136:562–566. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe
JD, Dai J, Urban N and Lubman DM: Validation of LRG1 as a potential
biomarker for detection of epithelial ovarian cancer by a blinded
study. PLoS One. 10:e01211122015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Mezencev R, Svajdler M, Benigno BB
and McDonald JF: Ectopic over-expression of miR-429 induces
mesenchymal-to-epithelial transition (MET) and increased drug
sensitivity in metastasizing ovarian cancer cells. Gynecol Oncol.
134:96–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ayhan A, Ertunc D, Tok EC and Ayhan A:
Expression of the c-Met in advanced epithelial ovarian cancer and
its prognostic significance. Int J Gynecol Cancer. 15:618–623.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang RT, Shi HR, Huang HL, Chen ZM, Liu
HN and Yuan ZF: Expressions of MACC1, HGF, and C-met protein in
epithelial ovarian cancer and their significance. Nan Fang Yi Ke Da
Xue Xue Bao. 31:1551–1555. 2011.(In Chinese). PubMed/NCBI
|
|
11
|
Chen J, Wang L, Matyunina LV, Hill CG and
McDonald JF: Overexpression of miR-429 induces
mesenchymal-to-epithelial transition (MET) in metastatic ovarian
cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu J, Wu X, Liu H, Liang Y, Gao X, Cai Z,
Wang W and Zhang H: Expression of microRNA-30a-5p in drug-resistant
and drug-sensitive ovarian cancer cell lines. Oncol Lett.
12:2065–2070. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong P, Xiong Y, Watari H, Hanley SJ,
Konno Y, Ihira K, Yamada T, Kudo M, Yue J and Sakuragi N: miR-137
and miR-34a directly target Snail and inhibit EMT, invasion and
sphere-forming ability of ovarian cancer cells. J Exp Clin Cancer
Res. 35:1322016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morgan RJ Jr, Alvarez RD, Armstrong DK,
Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray
HJ, Hakam A, et al: Ovarian cancer, version 2.2013. J Natl Compr
Canc Netw. 11:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei Z, Liu Y, Wang Y, Zhang Y, Luo Q, Man
X, Wei F and Yu X: Downregulation of Foxo3 and TRIM31 by miR-551b
in side population promotes cell proliferation, invasion, and drug
resistance of ovarian cancer. Med Oncol. 33:1262016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanlikilicer P, Saber M, Bayraktar R,
Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM,
Rodriguez-Aguayo C, et al: Ubiquitous release of exosomal tumor
suppressor miR-6126 from ovarian cancer cells. Cancer Res.
76:7194–7207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Azizmohammadi S, Azizmohammadi S, Safari
A, Kosari N, Kaghazian M, Yahaghi E and Seifoleslami M: The role
and expression of miR-100 and miR-203 profile as prognostic markers
in epithelial ovarian cancer. Am J Transl Res. 8:2403–2410.
2016.PubMed/NCBI
|
|
19
|
Li L, Xu QH, Dong YH, Li GX, Yang L, Wang
LW and Li HY: miR-181a upregulation is associated with
epithelial-to-mesenchymal transition (EMT) and multidrug resistance
(MDR) of ovarian cancer cells. Eur Rev Med Pharmacol Sci.
20:2004–2010. 2016.PubMed/NCBI
|
|
20
|
Meng X, Muller V, Milde-Langosch K,
Trillsch F, Pantel K and Schwarzenbach H: Diagnostic and prognostic
relevance of circulating exosomal miR-373, miR-200a, miR-200b and
miR-200c in patients with epithelial ovarian cancer. Oncotarget.
7:16923–16935. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sulaiman SA, Ab Mutalib NS and Jamal R:
miR-200c regulation of metastases in ovarian cancer: Potential role
in epithelial and mesenchymal transition. Front Pharmacol.
7:2712016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xia B, Li H, Yang S, Liu T and Lou G:
miR-381 inhibits epithelial ovarian cancer malignancy via YY1
suppression. Tumour Biol. 37:9157–9167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan W, Chen J, Chen Z and Chen H:
Deregulated miR-296/S100A4 axis promotes tumor invasion by inducing
epithelial-mesenchymal transition in human ovarian cancer. Am J
Cancer Res. 6:260–269. 2016.PubMed/NCBI
|
|
24
|
Wu X, Zhou J, Rogers AM, Jänne PA,
Benedettini E, Loda M and Hodi FS: c-Met, epidermal growth factor
receptor, and insulin-like growth factor-1 receptor are important
for growth in uveal melanoma and independently contribute to
migration and metastatic potential. Melanoma Res. 22:123–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Melo Gagliato D, Jardim DL, Falchook G,
Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu
S, et al: Analysis of MET genetic aberrations in patients with
breast cancer at MD Anderson Phase I unit. Clin Breast Cancer.
14:468–474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jardim DL, de Melo Gagliato D, Falchook
GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S,
Murphy MB, et al: MET aberrations and c-MET inhibitors in patients
with gastric and esophageal cancers in a phase I unit. Oncotarget.
5:1837–1845. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chiyomaru T, Seki N, Inoguchi S, Ishihara
T, Mataki H, Matsushita R, Goto Y, Nishikawa R, Tatarano S, Itesako
T, et al: Dual regulation of receptor tyrosine kinase genes EGFR
and c-Met by the tumor-suppressive microRNA-23b/27b cluster in
bladder cancer. Int J Oncol. 46:487–496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gardner FP, Serie DJ, Salomao DR, Wu KJ,
Markovic SN, Pulido JS and Joseph RW: c-MET expression in primary
and liver metastases in uveal melanoma. Melanoma Res. 24:617–620.
2014. View Article : Google Scholar : PubMed/NCBI
|
